Pharmaceuticals Sector Update : Underlying Growth Remains Strong despite Margin Headwinds by Choice Institutional Equities
Q1FY27E: Healthy Growth with Improved Demand and Product Scaleup; Margin Headwinds Remain Temporary
We expect our coverage universe to deliver another quarter of healthy growth in Q1FY27E. Growth is anticipated to be supported by continued scale-up of recent product launches, resilient demand in domestic chronic therapies and sustained momentum across emerging markets, which should largely offset competitive pressure in the US generics business. Margin, however, is likely to remain mixed in the near term due to pricing pressure and higher investment spending to support new launches and strategic acquisitions. We view these headwinds as largely transitory, as companies continue to invest in higher-margin speciality, biosimilar, peptide and complex product portfolios, which should support stronger profitability in the medium term.
Product Mix Improves as Complex Launches Gain Traction
We anticipate Q1FY27E to mark visible benefits from an improving product mix. These will include initial contributions from complex and speciality launches, including peptides, injectables, respiratory products and complex generics, complementing the base business. While the majority of this pipeline is inclined towards FY28E, we believe the ongoing shift towards higher-margin, value-added products represents a structural positive for the sector. This transition should enhance the quality of growth and support sustained margin expansion in the medium term.
Europe Emerging as the Next Export Growth Engine
While the US continues to be the largest export market for Indian pharmaceutical companies, Europe is emerging as an increasingly attractive growth opportunity, driven by greater emphasis on supplychain diversification and sourcing from reliable, GMP-compliant manufacturers. We believe this trend will support export growth, broaden the geographic revenue mix and reduce dependence on the US market in the medium term
Semaglutide Opportunity Shifts from Hype to Execution
Following the initial surge in industry optimism for Semaglutide, demand growth has begun to normalise towards a more sustainable trajectory. At the same time, including SUNP competition landscape has narrowed down, with only a handful, and DRRD from our coverage, appearing wellpositioned to capture a meaningful market share. While the long-term GLP-1 opportunity remains compelling, we believe near-term performance will increasingly be determined by execution capability, launch scale-up and market penetration rather than the size of the addressable market alone
Domestic API Manufacturing Gains Strategic Importance
Recent volatility in global API supply has reinforced the strategic importance of backward integration and PLI-driven capacity expansion. While India continues to rely on imports for several key intermediates, sustained investments in domestic manufacturing are expected to gradually strengthen supply security, improve cost-competitiveness and reduce structural import dependence in the medium term
Sector View
Despite near-term headwinds, we maintain a positive outlook on the sector, supported by a robust pipeline of launches, an ongoing shift towards complex generics and sustained growth in Biosimilars and CDMO segments, which together underpin long-term earnings visibility.
For Detailed Report With Disclaimer Visit. https://choicebroking.in/disclaimer
SEBI Registration no.: INZ 000160131
